Trade Bristol-Myers Squibb Co (Extended hours) - BMY CFD

What is Bristol-Myers Squibb Co.?

The Bristol-Myers Squibb Company is an international biopharmaceutical company specialising in discovering, developing and delivering innovative biopharmaceutical products and medicines to patients who suffer from serious diseases. Bristol-Myers Squibb provides medicines to help people fight cancer, hepatitis B and C, cardiovascular disease, HIV and AIDS. The company supplies its products to retail and wholesale pharmacies, governmental entities, and hospitals throughout the world.
 

What’s the history behind the company?

1858 – The Squibb corporation is founded by Edward Robinson Squibb in New York.
 
1887 – The Clinton Pharmaceutical company i purchased by William McLaren Bristol and John Ripley Myers. Two years later they rename it as “Bristol, Myers and Company”, and later, following Myers death in 1899 as the “Bristol-Myers Corporation”.
 
1903 – Sal Hepatica, a laxative salt is developed and released marking the first product for the company.
 
1943 – Acquisition of Cheplin Biological Laboratories, Bristol laboratories in 1945 creating antibiotics, is met with competition from Squibbs.
 
1989 – Bristol-Myers merges with Squibb to form Bristol-Myers Squibb, creating one of the world’s largest pharmaceutical companies.
 
1998 – Development of Excedrin Migraine, one of the first migraine medications available without a prescription in the US.
 
2004 – Bristol-Myers Squibb pays $150 million in a settlement for accounting fraud, the company does not admit or deny guilt. In 2006, the company is hit again by charges and pays $2.1 million to the Federal Trade Commission.
 
2008 – The company undertakes a number of partnerships, including therapy for cardiovascular diseases with KAI pharmaceuticals, cancer therapies with Kosan, and two novel therapies for cancer with Exelixis. These collaborations continue into 2009 with more added.
 
2010 – Lamberto Andreotti took over as CEO of Bristol-Myers Squibb. By 2012, the company’s net sales reach $17.6 billion.
 
2015 – Dr. Giovanni Caforio becomes the head of the company.
 

About the company

Bristol-Myers Squibb operates worldwide with locations such as Asia, including China and Japan, Southeast Asia in Bangalore India, across Europe in Belgium, England, France, Ireland and Italy, and North America. This includes a number of research and development facilities, vital to the creation of new pharmaceutical products.
 
Across its facilities, the company employs approximately 23,700 people. To date, Dr. Giovanni Caforio is the Chairman and CEO of the company with Charles Bancroft as CFO.
 
The company has numerous awards and achievements, including 2018 Best-of-the-Best Corporations for Inclusion by National Business Inclusion Consortium, Fortune’s World’s Most Admired Companies, Dow Jones' 2017 North American Index of Leading Sustainable Companies, and Forbes America’s Best Employers for 2016.
 

Key Statistics

  • Revenue in 2017 – $20.78 billion
  • Net income in 2017 – $975 million
  • Total assets in 2017 – 33.55 billion
  • Total equity in 2017 – 11.85 billion

Major acquisitions

  • Adnexus Therapeutics – 2007
  • Kosan Biosciences – 2008
  • Medarex – 2009
  • ZymoGenetics – 2010
  • Amira Pharmaceuticals – 2011
  • Inhibitex Inc. – 2012
  • Amylin Pharmaceuticals and AstraZeneca – 2018
  • iPierian – 2014
  • Flexus Biosciences – 2015
  • Cardioxyl – 2015
  • Padlock Therapeutics – 2016
  • Cormorant Pharmaceuticals – 2016
  • IFM Therapeutics – 2017

Where is Bristol-Myers Squibb Co. traded?

Bristol-Myers Squibb is traded on the New York Stock Exchange (NYSE) under the ticker BMY. It is also a component of the S&P 100 and S&P 500. Trade the latest Bristol-Myers Squibb share price with Capital.com, explore the most up-to-date BMY charts, and delve into this pharmaceutical company.

Latest shares articles

Top 5 biggest short squeezes
Top 5 biggest short squeezes
Top 5 biggest short squeezes
50 minutes ago
Market Mondays: Equities shrug off trade threats—but correction risk builds
Market momentum remains strong despite Trump's latest tariff threats as hope for deals continues
5 hours ago
UK GDP contracts again in May as FTSE 100 eyes new highs
The UK economy experiences negative growth in May leading markets to price in a rate cut from the BOE in August
08:31, 11 July 2025
Nvidia stock forecast: Third-party price target
Nvidia stock forecast: Third-party price target
Discover third-party Nvidia stock forecast predictions for 2025-2030 and beyond, with analyst targets, historical prices, and trading strategies.
14:51, 10 July 2025

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
Victor Flemming Nandwa Søder

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-07-01
Perry Reineke

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-06-29
proinpro

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

2025-06-27
Gio Gvazava

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-22
Douglas

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-22
Jean A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-19
foobarbeer

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-06-19
Casaubon70

Love the TV integration. Makes traders life smooth and comfortable.

2025-06-19
dgogidze7

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-05-30
Brigman

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-05-24
Radioilluminati

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-04-29
dmjnoor

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-05-20
GemzT

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-03-24
Debbie P

The best trading company I've found so far and so easy to use.

2025-02-06
Nouman Butt

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading CFDs